Retrospective Evaluation of Nivolumab in Adjuvant Esophageal Cancer/Gastroesophageal Junction Cancer

Bristol-Myers Squibb (BMS)

Status: Completed

Conditions: Gastroesophageal Junction Cancer; Esophageal Cancer

Treatments: Drug: Nivolumab

Study type: Observational

Funder types: Industry

Identifiers

NCT06499298

CA209-1428

Details and patient eligibility

About

The purpose of this study is to describe the real-world effectiveness and patterns of use of adjuvant nivolumab in adult participants with Stage II/III Esophageal Cancer/Gastroesophageal Junction Cancer (EC/GEJC) in China.

Enrollment: 64 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Participants aged 18 years or older at the index date
• All patients must have Stage II or Stage III carcinoma of the esophagus or gastroesophageal junction and have histologically or cytologically confirmed predominant adenocarcinoma or squamous cell carcinoma esophageal or gastroesophageal junction cancer at the time of initial diagnosis.
• Participants initiated nivolumab in adjuvant Esophageal Cancer (EC) or gastroesophageal junction cancer (GEJC) treatment within the index window.

Exclusion criteria

• Participation in a clinical trial of an investigational drug concurrently during the adjuvant nivolumab treatment.
• From the date of diagnosis of EC or GJEC to data end period, patients were diagnosed with a primary diagnosis of a cancer other than EC or GJEC that requires systemic or other treatment

Trial design

64 participants in 1 patient group

Participants receiving adjuvant nivolumab

Treatment:

Drug: Nivolumab